Vetter, a global contract development and manufacturing organization (CDMO) specializing in injectable drugs, has officially started construction on a new manufacturing facility in Saarlouis, Germany. The project represents an investment of approximately €500 million and is aimed at increasing the company’s production capacity for sterile injectable medications.
The company said the first construction phase includes development of a 50,000 sqm manufacturing facility designed for commercial production of injectable drugs, including cleanroom capacity for syringes and vials. Vetter stated that the site is scheduled for commissioning in 2031.
According to the company, the Saarlouis facility is expected to create approximately 1,500 jobs by the final stage of the first construction phase. Representatives from regional and state government, project partners, and Vetter attended the groundbreaking ceremony.
Vetter said the project forms part of its broader strategy to strengthen manufacturing operations in Europe and the United States. The company added that the new site will support customers developing complex and innovative injectable drug products.
Photo: Vetter
Bron: Pharmasouce, Vetter